Glutamate transporters, EAAT1 and EAAT2, are potentially important in the pathophysiology and treatment of schizophrenia and affective disorders
Georgia M Parkin, Madhara Udawela, Andrew Gibbons, Brian Dean, Molecular Psychiatry Laboratory, the Florey Institute of Neuroscience and Mental Health, Parkville VIC 3052, Australia
Georgia M Parkin, Madhara Udawela, Brian Dean, CRC for Mental Health, Carlton VIC 3053, Australia
Brian Dean, Research Centre for Mental Health, the Faculty of Health, Arts and Design, Swinburne University, Hawthorne VIC 3122, Australia
Author contributions: Parkin GM drafted the manuscript; Udawela M, Gibbons A and Dean B provided critical revisions to the manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest for this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Georgia M Parkin, BSc, MSc, Molecular Psychiatry Laboratory, the Florey Institute of Neuroscience and Mental Health, 30 Royal Parade, Parkville VIC 3052, Australia. email@example.com
Received: March 19, 2018
Peer-review started: March 19, 2018
First decision: May 8, 2018
Revised: May 15, 2018
Accepted: June 8, 2018
Article in press: June 9, 2018
Published online: June 28, 2018